公开(公告)号：US11795150B2

公开(公告)日：2023-10-24

申请号：US16535453

申请日：2019-08-08

Applicant: Philera New Zealand Limited

Inventor： Marco Jonas ,  Irene Vaulont ,  Antonio Soi ,  Gunther Schmidt

IPC: C07D233/02 ,  C07C55/10 ,  C07C57/145 ,  C07C57/15 ,  C07C209/48 ,  C07C209/62 ,  C07C211/10 ,  C07C211/14 ,  C07D233/26 ,  C07C211/13 ,  C07C209/76 ,  C07C255/30

CPC classification number: C07D233/02 ,  C07C55/10 ,  C07C57/145 ,  C07C57/15 ,  C07C209/48 ,  C07C209/62 ,  C07C209/76 ,  C07C211/10 ,  C07C211/13 ,  C07C211/14 ,  C07C255/30 ,  C07D233/26 ,  C07B2200/13 ,  C07C209/48 ,  C07C211/14 ,  C07C209/62 ,  C07C211/14 ,  C07C209/48 ,  C07C211/10 ,  C07C209/62 ,  C07C211/10

Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

公开(公告)号：US20180230091A1

公开(公告)日：2018-08-16

申请号：US15751547

申请日：2016-08-10

Applicant: ALZHEON, INC.

Inventor： Petr KOCIS ,  Martin TOLAR ,  John HEY

IPC: C07C309/26 ,  C07C309/19 ,  A61P25/28

CPC classification number: C07C309/26 ,  A61P25/28 ,  C07B2200/07 ,  C07C309/19 ,  C07C309/27 ,  C07C317/50 ,  C07C323/59 ,  C07C323/60 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/14 ,  C07D207/16 ,  C07D209/20 ,  C07D211/58 ,  C07D233/26 ,  C07D295/185 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07K5/00 ,  C07K5/06165

Abstract: Compounds, pharmaceutical compositions, methods and kits are described for treating or preventing neurodegenerative diseases such as Alzheimer's disease.

公开(公告)号：US20170320895A1

公开(公告)日：2017-11-09

申请号：US15599769

申请日：2017-05-19

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Roland Gendron ,  Melissa Fleury ,  Adam D. Hughes

IPC: C07D498/08 ,  A61K31/42 ,  C07D413/12 ,  C07D413/06 ,  C07D413/04 ,  C07D409/06 ,  C07D405/12 ,  C07D403/06 ,  C07D403/04 ,  C07D401/06 ,  C07D401/04 ,  C07D333/70 ,  C07D333/40 ,  C07D307/68 ,  C07D277/56 ,  C07D277/46 ,  C07D271/06 ,  C07D263/56 ,  C07D263/34 ,  C07D261/20 ,  C07D261/18 ,  C07D261/12 ,  C07D257/04 ,  C07D249/18 ,  C07D249/12 ,  C07D249/10 ,  C07D249/08 ,  C07D249/04 ,  C07D241/24 ,  C07D239/36 ,  C07D239/34 ,  C07D237/24 ,  C07D237/04 ,  C07D233/90 ,  C07D233/26 ,  C07D231/14 ,  C07D213/81 ,  C07D213/80 ,  C07D213/79 ,  C07D207/34 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/422 ,  C07D471/04 ,  C07D498/04

CPC classification number: C07D498/08 ,  A61K31/42 ,  A61K31/422 ,  A61K31/5377 ,  A61K45/06 ,  C07D207/34 ,  C07D213/79 ,  C07D213/80 ,  C07D213/81 ,  C07D231/14 ,  C07D233/26 ,  C07D233/90 ,  C07D237/04 ,  C07D237/24 ,  C07D239/34 ,  C07D239/36 ,  C07D241/24 ,  C07D249/04 ,  C07D249/08 ,  C07D249/10 ,  C07D249/12 ,  C07D249/18 ,  C07D257/04 ,  C07D261/12 ,  C07D261/18 ,  C07D261/20 ,  C07D263/34 ,  C07D263/56 ,  C07D271/06 ,  C07D277/46 ,  C07D277/56 ,  C07D307/68 ,  C07D333/40 ,  C07D333/70 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/12 ,  C07D409/06 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D471/04 ,  C07D498/04

Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

公开(公告)号：US09731016B2

公开(公告)日：2017-08-15

申请号：US15089568

申请日：2016-04-03

Applicant: Marina Biotech, Inc.

Inventor： Steven C. Quay ,  Michael E. Houston, Jr. ,  Pierrot Harvie ,  Roger C. Adami ,  Renata Fam ,  Mary Prieve ,  Kathy Fosnaugh ,  Shaguna Seth

IPC: A61K47/18 ,  A61K48/00 ,  C07C235/02 ,  C12N15/88 ,  C07D213/56 ,  C07C279/14 ,  C07D213/40 ,  C07D233/26 ,  C12N15/11 ,  A61K47/44 ,  C12N15/113 ,  A61K31/7088 ,  A61K47/22 ,  C07D233/64 ,  A61K47/28 ,  C07C279/12 ,  A61K9/127

CPC classification number: A61K47/183 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/1272 ,  A61K31/7088 ,  A61K47/18 ,  A61K47/22 ,  A61K47/28 ,  A61K47/44 ,  A61K48/0025 ,  A61K48/0033 ,  C07C235/02 ,  C07C279/12 ,  C07C279/14 ,  C07D213/40 ,  C07D213/56 ,  C07D233/26 ,  C07D233/64 ,  C12N15/111 ,  C12N15/113 ,  C12N15/1131 ,  C12N15/1138 ,  C12N15/88 ,  C12N2310/14 ,  C12N2320/32 ,  Y10S514/943

Abstract: This disclosure provides a range of tyrosine amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

公开(公告)号：US20160185716A1

公开(公告)日：2016-06-30

申请号：US14907321

申请日：2014-07-30

Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Inventor： Eduardo M. Sotomayor ,  Joel A. Bergman ,  Alan P. Kozikowski ,  Alejandro V. Lagra ,  Karrune V. Woan

IPC: C07C275/34 ,  A61K45/06 ,  A61K31/185 ,  C07D209/14 ,  A61K31/4045 ,  C07D213/75 ,  A61K31/44 ,  C07D261/14 ,  A61K31/42 ,  A61K31/437 ,  C07D239/42 ,  A61K31/505 ,  C07D231/56 ,  A61K31/416 ,  C07C275/40 ,  A61K31/17

CPC classification number: C07C275/34 ,  A61K31/17 ,  A61K31/185 ,  A61K31/4045 ,  A61K31/416 ,  A61K31/42 ,  A61K31/437 ,  A61K31/44 ,  A61K31/505 ,  A61K45/06 ,  C07C275/28 ,  C07C275/40 ,  C07D209/14 ,  C07D213/75 ,  C07D231/56 ,  C07D233/26 ,  C07D233/74 ,  C07D233/78 ,  C07D239/42 ,  C07D261/14 ,  C07D295/13

Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Specifically, the disclosed subject matter relates to compounds having activity as selective HDAC6 inhibitors, methods of making and using the compounds, and compositions comprising the compounds. In still further aspects, the disclosed subject matter relates to methods for treating oncological disorders in a patient. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

Abstract translation: 公开了具有式I的选择性组蛋白失活酶抑制剂（HDACi）。具体地，所公开的主题涉及具有作为选择性HDAC6抑制剂的活性的化合物，制备和使用该化合物的方法，以及包含该化合物的组合物。 在另外的方面，所公开的主题涉及用于治疗患者的肿瘤疾病的方法。 还公开了制备和使用这些抑制剂治疗癌症，特别是黑素瘤的方法。

公开(公告)号：US20160102060A1

公开(公告)日：2016-04-14

申请号：US14736074

申请日：2015-06-10

Applicant: PhilEra New Zealand Limited

Inventor： Marco Jonas ,  Irene Vaulont ,  Antonio Soi ,  Gunther Schmidt

IPC: C07D233/02 ,  C07C255/30 ,  C07C211/14

CPC classification number: C07D233/02 ,  C07B2200/13 ,  C07C55/10 ,  C07C57/145 ,  C07C57/15 ,  C07C209/48 ,  C07C209/62 ,  C07C209/76 ,  C07C211/10 ,  C07C211/13 ,  C07C211/14 ,  C07C255/30 ,  C07D233/26

Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

公开(公告)号：US09011804B2

公开(公告)日：2015-04-21

申请号：US14001848

申请日：2012-11-02

Applicant: Kyushu University, National University Corporation ,  Sumitomo Metal Mining Co., Ltd.

Inventor： Masahiro Goto ,  Fukiko Kubota ,  Yuzo Baba

IPC: B01D11/00 ,  C22B3/00 ,  C01F17/00 ,  C22B3/26 ,  C22B59/00 ,  C22B23/00 ,  C07D233/26 ,  C07C237/06 ,  H01M8/00 ,  H01M10/54

CPC classification number: C22B23/0461 ,  B01D11/00 ,  C01F17/0006 ,  C07C237/06 ,  C07D233/26 ,  C22B3/0005 ,  C22B3/0032 ,  C22B23/00 ,  C22B23/0453 ,  C22B59/00 ,  H01M8/008 ,  H01M10/54 ,  Y02P10/234 ,  Y02W30/84 ,  Y02W30/86

Abstract: The objective of the present invention is to selectively extract cobalt from an acidic solution containing a high concentration of manganese. This cobalt extraction method extracts cobalt from an acidic solution containing manganese and cobalt by subjecting the acidic solution to solvent extraction by means of a valuable metal extraction agent comprising an amide derivative represented by general formula (I). The valuable metal extraction agent is represented by the general formula. In the formula: R1 and R2 each represent the same or different alkyl group; R3 represents a hydrogen atom or an alkyl group; and R4 represents a hydrogen atom or any given group aside from an amino group bonded to the α carbon as an amino acid. Preferably, the general formula has a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit, or an N-methylglycine unit. Preferably, the pH of the acidic solution is 3.5-5.5 inclusive.

Abstract translation: 本发明的目的是从含有高浓度锰的酸性溶液中选择性提取钴。 该钴提取方法通过使含有由通式（I）表示的酰胺衍生物的贵金属萃取剂进行溶剂萃取，从含有锰和钴的酸性溶液中提取钴。 有价值的金属萃取剂由通式表示。 式中R 1和R 2各自表示相同或不同的烷基; R3表示氢原子或烷基; 并且R 4表示氢原子或除了与作为氨基酸的α碳键合的氨基以外的任何给定基团。 优选地，通式为甘氨酸单元，组氨酸单元，赖氨酸单元，天冬氨酸单元或N-甲基甘氨酸单元。 优选地，酸性溶液的pH值为3.5-5.5（含）。

公开(公告)号：US20150017233A1

公开(公告)日：2015-01-15

申请号：US14496200

申请日：2014-09-25

Applicant: Marina Biotech, Inc.

Inventor： Steven C. Quay ,  Michael E. Houston, JR. ,  Pierrot Harvie ,  Roger C. Adami ,  Renata Fam ,  Mary G. Prieve ,  Kathy L. Fosnaugh ,  Shaguna Seth

IPC: A61K9/127 ,  A61K47/18 ,  C07D233/64 ,  A61K47/22 ,  C07D213/56 ,  A61K31/7088 ,  C07C279/14

CPC classification number: A61K47/183 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/1272 ,  A61K31/7088 ,  A61K47/18 ,  A61K47/22 ,  A61K47/28 ,  A61K47/44 ,  A61K48/0025 ,  A61K48/0033 ,  C07C235/02 ,  C07C279/12 ,  C07C279/14 ,  C07D213/40 ,  C07D213/56 ,  C07D233/26 ,  C07D233/64 ,  C12N15/111 ,  C12N15/113 ,  C12N15/1131 ,  C12N15/1138 ,  C12N15/88 ,  C12N2310/14 ,  C12N2320/32 ,  Y10S514/943

Abstract: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

Abstract translation: 本公开提供了一系列用于药物递送，治疗以及疾病和病症的诊断和治疗的氨基酸脂质化合物和组合物。 氨基酸脂质化合物和组合物可用于向细胞，组织，器官和受试者递送各种试剂，例如核酸治疗剂。

公开(公告)号：US20150005316A1

公开(公告)日：2015-01-01

申请号：US14269420

申请日：2014-05-05

Applicant: Sprout Pharmaceuticals, Inc.

Inventor： Carlo Bombarda ,  Enrica Dubini ,  Antoine Ezhaya

IPC: C07D235/26

CPC classification number: A61K31/496 ,  C07D233/26 ,  C07D235/26 ,  C07D403/06

Abstract: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.

公开(公告)号：US20140328737A1

公开(公告)日：2014-11-06

申请号：US14001848

申请日：2012-11-02

Applicant: Kyushu University, National University Corporation ,  SUMITOMO METAL MINING CO., LTD.

Inventor： Masahiro Goto ,  Fukiko Kubota ,  Yuzo Baba

IPC: C22B3/00

CPC classification number: C22B23/0461 ,  B01D11/00 ,  C01F17/0006 ,  C07C237/06 ,  C07D233/26 ,  C22B3/0005 ,  C22B3/0032 ,  C22B23/00 ,  C22B23/0453 ,  C22B59/00 ,  H01M8/008 ,  H01M10/54 ,  Y02P10/234 ,  Y02W30/84 ,  Y02W30/86

Abstract: The objective of the present invention is to selectively extract cobalt from an acidic solution containing a high concentration of manganese. This cobalt extraction method extracts cobalt from an acidic solution containing manganese and cobalt by subjecting the acidic solution to solvent extraction by means of a valuable metal extraction agent comprising an amide derivative represented by general formula (I). The valuable metal extraction agent is represented by the general formula. In the formula: R1 and R2 each represent the same or different alkyl group; R3 represents a hydrogen atom or an alkyl group; and R4 represents a hydrogen atom or any given group aside from an amino group bonded to the α carbon as an amino acid. Preferably, the general formula has a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit, or an N-methylglycine unit. Preferably, the pH of the acidic solution is 3.5-5.5 inclusive.

Abstract translation: 本发明的目的是从含有高浓度锰的酸性溶液中选择性提取钴。 该钴提取方法通过使含有由通式（I）表示的酰胺衍生物的贵金属萃取剂进行溶剂萃取，从含有锰和钴的酸性溶液中提取钴。 有价值的金属萃取剂由通式表示。 式中R 1和R 2各自表示相同或不同的烷基; R3表示氢原子或烷基; 并且R 4表示氢原子或除了与作为氨基酸的α碳键合的氨基以外的任何给定基团。 优选地，通式为甘氨酸单元，组氨酸单元，赖氨酸单元，天冬氨酸单元或N-甲基甘氨酸单元。 优选地，酸性溶液的pH值为3.5-5.5（含）。